Search results
Showing 61 to 75 of 161 results for infarction
Evidence-based recommendations on apixaban (Eliquis) for preventing stroke and systemic embolism in adults with non-valvular atrial fibrillation.
Spartan RX point-of-care CYP2C19 test to guide treatment in acute coronary syndrome (MIB223)
NICE has developed a medtech innovation briefing (MIB) on Spartan RX point-of-care CYP2C19 test to guide treatment in acute coronary syndrome .
Evidence-based recommendations on icosapent ethyl (Vazkepa) with statin therapy for reducing the risk of cardiovascular events in adults with raised triglycerides.
ClearWay RX for drug delivery to coronary artery thrombotic lesions (MIB55)
NICE has developed a medtech innovation briefing (MIB) on ClearWay RX for drug delivery to coronary artery thrombotic lesions
Transcatheter aortic valve implantation (TAVI) for native aortic valve regurgitation (HTG752)
Evidence-based recommendations on transcatheter aortic valve implantation (TAVI) for native aortic valve regurgitation. This involves implanting a replacement valve inside the faulty native valve.
View recommendations for HTG752Show all sections
Summary of the evidence on avanafil for treating erectile dysfunction to inform local NHS planning and decision-making
NICE has developed a medtech innovation briefing (MIB) on Optowire for measuring fractional flow reserve .
Non-alcoholic fatty liver disease (NAFLD): assessment and management (NG49)
This guideline covers how to identify the adults, young people and children with non-alcoholic fatty liver disease (NAFLD) who have advanced liver fibrosis and are most at risk of further complications. It outlines the lifestyle changes and pharmacological treatments that can manage NAFLD and advanced liver fibrosis.
Summary of the evidence on omega-3 fatty acid medicines for treating schizophrenia to inform local NHS planning and decision-making
Drug-eluting stents for the treatment of coronary artery disease (TA152)
Evidence-based recommendations on using drug-eluting stents in adults.
Optical coherence tomography to guide percutaneous coronary intervention (HTG332)
Evidence-based recommendations on optical coherence tomography to guide percutaneous coronary intervention. This involves using near-infrared light to produce high-resolution images of blood vessel walls.
Impella 2.5 for haemodynamic support during high-risk percutaneous coronary interventions (MIB89)
NICE has developed a medtech innovation briefing (MIB) on Impella 2.5 for haemodynamic support during high-risk percutaneous coronary interventions .
HeartFlow FFRCT for estimating fractional flow reserve from coronary CT angiography (HTG429)
Evidence-based recommendations on HeartFlow FFRCT for estimating fractional flow reserve from coronary CT angiography.
Digital platforms to support cardiac rehabilitation: early value assessment (HTG761)
Early value assessment (EVA) on digital platforms to support cardiac rehabilitation.
Evidence-based recommendations on bevacizumab (Avastin), sorafenib (Nexavar), sunitinib (Sutent) and temsirolimus (Torisel) for treating advanced or metastatic renal cell carcinoma in adults.